Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging

David G. Rizik; Bimal B. Padaliya

Journal ArticleOPEN ACCESS

Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging

Journal of Interventional Cardiology (2016) 29(5) 546-548

DOI: 10.1111/joic.12329

6Citations

6Readers

Abstract

Drug eluting metallic stents have been the “gold standard” in the percutaneous management of coronary artery disease. Recent publications have suggested that the ABSORBTM bioresorbable vascular scaffold (BVS) may represent a reasonable alternative, in well selected cases.

Cite

CITATION STYLE

APA

Rizik, D. G., & Padaliya, B. B. (2016). Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging. Journal of Interventional Cardiology, 29(5), 546–548. https://doi.org/10.1111/joic.12329

Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging

Abstract

Cite

Register to see more suggestions